CALGARY, ALBERTA - Stem Cell Therapeutics Corp. (SCT) announced in a Monday press release that it has been issued two corresponding patents to strengthen its Intellectual Property (IP) landscape through United States and Australia.

The US Patent, numbered 7,393,830 and entitled "Prolactin induced increase in neural stem cell numbers" was issued July 1, 2008.

The Australian Patent, numbered 2002325711 and entitled "Prolactin induced increase in neural stem cell numbers and therapeutical use thereof" was issued January 10, 2008. These are the first patents to issue in this patent family.

"What is particularly important about these patents is that they cover the use of prolactin alone, as well as in combination with other therapeutics that augment recovery and therefore provide a broad base of protection,” President and CEO of SCT Dr. Alan Moore commented.

“We have the exclusive right to the use of prolactin for treating neurodegenerative diseases and therefore have a strong foundation to develop many possible products using prolactin, either as a single therapeutic or in combination with other neurogenic agents,” he added.

“For example, this Intellectual Property supports programs currently under development using prolactin alone or with anti-inflammatories to treat multiple sclerosis and using a combination of prolactin and EPO to treat other neurodegenerative diseases," Moore continued.

Stem Cell Therapeutics Corp. is a Canadian public biotechnology company focused on the development and commercialization of drug-based therapies to treat central nervous system diseases.

Source: ag-IP news